Research
Hormonal
Increased heart rate was observed across NN1706 treatment cohorts.
Clinicians should monitor heart rate in patients receiving NN1706 treatment.
StrongQualifiesmedium confidence
Increased heart rate was observed across NN1706 treatment cohorts.
Why this rating
The claim is based on observations from clinical treatment cohorts.
Source
A once-daily GLP-1/GIP/glucagon receptor tri-agonist (NN1706) lowers body weight in rodents, monkeys and humans
Brian Finan et al. · Molecular Metabolism · 2025
DOI 10.1016/j.molmet.2025.102129
otherCited 13×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →